Loading clinical trials...

Pharmacogenetics of Ace Inhibitor-Associated Angioedema | Clinical Trials | Clareo Health

COMPLETEDNA

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1

NCT01413542•Vanderbilt University

Summary

The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

Detailed Description

To test the hypothesis that DPPIV inhibition with sitagliptin potentiates the vasodilator response to substance P in the presence of ACE inhibition with enalaprilat and to BNP and GLP-1 even in the presence of ACE inhibition. The aim promises to provide important new data regarding the mechanism of action of DPPIV inhibitors and interactive effects of these two drug classes used in a growing population of diabetic patients.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age 18 to 65 inclusive
•Men and women
•Black and White Americans
•BMI \<25
•For female subjects:
•Postmenopausal status for at least 1 year
•Status post surgical sterilization
•If childbearing potential, utilization of a barrier method of birth control and willingness to undergo blood B-hcg testing prior to drug treatment and on every study day

Exclusion Criteria

•Smoking
•Diabetes type 1 or 2, as defined by a fasting glucose of 126 mg/dl or greater or the use of anti-diabetic medication
•Hypertension as defined by an untreated seated SBP greater than 140 mmHg an untreated DBP greater than 90 mmHg or the use of antihypertensives
•History of reported or recorded hypoglycemia (plasma glucose less than 70 mg/dl)
•Pregnancy
•Breast-feeding
•Use of hormone replacement therapy
•The use of contraceptive therapy
•Use of any medication other than multivitamin
•Hematocrit \<35%
+11 more criteria

Locations (1)

Vanderbilt University- General Clinic Research Center

Nashville, Tennessee, United States

Key Dates

Start Date

November 1, 2011

Primary Completion Date

July 1, 2013

Completion Date

July 1, 2014

Last Updated

November 4, 2015

Enrollment

ACTUAL participants

Conditions

HypertensionDiabetes Type 2

Interventions

Sitagliptin (DPP4 inhibitor)

DRUG

Substance P,

DRUG

bradykinin

DRUG

enalaprilat (ACE inhibitor)

DRUG

Glucagon-like peptide 1

DRUG

brain natriuretic peptide

DRUG

Natural History of Noncirrhotic Portal Hypertension

NCT02417740

Cystic FibrosisImmunologic Deficiency Syndrome+3 more

View study

RECRUITING

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

NCT07480265

Hypertension (HTN)Hyperhomocysteinemia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 4, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Inclusion Criteria

Exclusion Criteria

Natural History of Noncirrhotic Portal Hypertension

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication

Penn Medicine Healthy Heart

Preliminary Human Trials of F230 Tablets